Get the Stockscreener App
1.28
0.78%
-0.01
After Hours:
1.34
0.06
+4.69%
Evogene Ltd stock is traded at $1.28, with a volume of 33,347.
It is down -0.78% in the last 24 hours and up +0.79% over the past month.
Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.
See More
Previous Close:
$1.29
Open:
$1.33
24h Volume:
33,347
Relative Volume:
0.43
Market Cap:
$11.24M
Revenue:
$5.64M
Net Income/Loss:
$-23.88M
P/E Ratio:
-2.4151
EPS:
-0.53
Net Cash Flow:
$-22.36M
1W Performance:
+2.40%
1M Performance:
+0.79%
6M Performance:
+21.99%
1Y Performance:
-50.29%
1-Day Range:
$1.2704
$1.33
1-Week Range:
$1.20
$1.50
52-Week Range:
$0.95
$2.8699
Evogene Ltd Stock (EVGN) Company Profile
Compare EVGN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EVGN
Evogene Ltd
|
1.28 | 11.24M | 5.64M | -23.88M | -22.36M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Evogene Ltd Stock (EVGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-08-21 | Initiated | ROTH Capital | Buy |
| Jul-29-21 | Initiated | Aegis Capital | Buy |
| Dec-01-20 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-16-13 | Initiated | Oppenheimer | Outperform |
Evogene Ltd Stock (EVGN) Latest News
Why Evogene Ltd. stock is in analyst buy zoneJuly 2025 Patterns & Fast Exit and Entry Strategy Plans - newser.com
Is Evogene Ltd. forming a reversal patternRisk Management & Stepwise Trade Signal Implementation - newser.com
Can Evogene Ltd. stock withstand economic slowdownMarket Risk Summary & Entry Point Strategy Guides - newser.com
Backtesting results for Evogene Ltd. trading strategiesWeekly Market Report & Safe Entry Point Identification - newser.com
Using data tools to time your Evogene Ltd. exitQuarterly Portfolio Review & High Conviction Buy Zone Alerts - newser.com
Weiss Ratings Reiterates “Sell (E+)” Rating for Evogene (NASDAQ:EVGN) - Defense World
NovoCure (NASDAQ:NVCR) vs. Evogene (NASDAQ:EVGN) Head-To-Head Analysis - Defense World
Evogene Ltd Stock Analysis and ForecastSector-Based Investing & Minimal Capital Investment - earlytimes.in
What catalysts could drive Evogene Ltd. stock higherJuly 2025 Setups & Consistent Growth Equity Picks - newser.com
Why retail investors favor Evogene Ltd. stockGDP Growth & Weekly High Return Forecasts - newser.com
Is Evogene Ltd. stock a safe buy before earningsPortfolio Growth Summary & Technical Entry and Exit Alerts - newser.com
Statistical indicators supporting Evogene Ltd.’s strengthFed Meeting & Daily Chart Pattern Signal Reports - newser.com
Evogene Ltd. Releases Financial Results for First Half of 2025 - MSN
Can Evogene Ltd. recover in the next quarter2025 Breakouts & Breakdowns & Free Reliable Trade Execution Plans - newser.com
How to read the order book for Evogene Ltd.2025 Institutional Moves & Real-Time Volume Analysis - newser.com
What analysts say about Evogene Ltd stockAnalyst Downgrades & Low Risk Capital Growth Plans - earlytimes.in
What drives Evogene Ltd stock priceRetail Investor Activity & Small Capital Investment Tips - earlytimes.in
Evogene Ltd Stock (EVGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):